Tag Archives: hypertension
The levels of visfatin and toll-like receptors in arterial hypertension and type 2 diabetes mellitus
N. Pokrovska1, S. Mahiiovych1, I. Fomenko2,
L. Biletska2, H. Sklyarova3, L. Kobylinska2*
1Department of Therapy No 1, Medical Diagnostics and Hematology and Transfusion
of FPGE, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine;
2Department of Biochemistry, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine;
3Department of Family Medicine FPGE, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine;
*e-mail: lesyaivanivna.biochemistry@gmail.com
Received: 28 January 2024; Revised: 26 February 2024;
Accepted: 27 February 2024; Available on-line: April 2024
Hypertension and type 2 diabetes mellitus (DM) remain widespread diseases that are becoming more prevalent. The role of visfatin and toll-like receptor (TLR) molecules in the pathogenesis of these diseases requires further research. Our aim was to study changes in visfatin and TLR levels in patients with hypertension and type 2 diabetes. Fifty-one patients were examined and divided into two groups: group 1 included 27 patients with hypertension and group 2 included 24 people with hypertension and type 2 DM. The control group included 18 practically healthy people. All individuals underwent general blood test, coagulogram, biochemical blood test, enzyme immunoassay to determine the level of visfatin and TLR in the blood serum and echocardiography. Hypertrophy of the walls of the left ventricle (LV) was observed in patients of two observed groups. The most common type of LV geometry was concentric hypertrophy (41.2%). The level of visfatin was significantly higher in patients of group 1, while in patients of group 2 it was decreased (P ˂ 0.05) and the level of TLR was increased (P ˂ 0.05). The elevated level of TLR in the serum of patients with hypertension can be considered a factor of low-grade inflammation, especially in combination with type 2 DM. The increase in the concentration of visfatin in hypertension serves as a more sensitive marker compared to TLR regarding the risk of developing comorbid cardiovascular pathology. The therapeutic treatments of patients with type 2 DM cause a reduction in the concentration of visfatin induced by hypertension.
The level of nitric oxide and arginase activity in patients with arterial hypertension and diabetes mellitus during COVID-19
O. Y. Sklyarova1, S. R. Mahiiovych2, N. V. Denysenko3,
L. I. Kobylinska3*, Y. Y. Sklyarov2
1Department of Family Medicine FPGE, Danylo Halytsky Lviv National Medical University, Ukraine;
2Department of Therapy No 1 and Medical Diagnostics FPGE, Danylo Halytsky Lviv National Medical University, Ukraine;
3Department of Biological Chemistry, Danylo Halytsky Lviv National Medical University, Ukraine;
*e-mail: lesyaivanivna.biochemistry@gmail.com
Received: 28 September 2022; Revised: 06 November 2022;
Accepted: 11 November 2022; Available on-line: 19 December 2022
The aim of this study was to assess the level of nitric oxide production and arginase activity in patients with arterial hypertension and type II diabetes mellitus during infection with SARS-CoV-2. The study groups included patients with arterial hypertension, patients with arterial hypertension combined with a severe course of COVID-19 and patients who, in addition to arterial hypertension and COVID-19, were suffering from type II diabetes mellitus. The volunteers without any clinical signs of diseases and normal blood pressure formed the control group. It has been established that arterial hypertension, combined with COVID-19 occurs along with reduced L-arginine, nitric oxide, superoxide dismutase activity and increased arginase activity. At the same time, the presence of arterial hypertension in patients with diabetes and coronavirus disease is accompanied by a decline in the content of L-arginine and arginase activity. Our study’s results may help scientists find new pharmacological targets in the future treatment of coronavirus disease and comorbid disorders.
Practical development of laboratory of biologics technology of the Palladin Institute of Biochemistry of NAS of Ukraine for the period 1991-2010
G. G. Lugovska, R. P. Vynogradova, N. E. Lugovska,
I. G. Chernysh, S. P. Yurasova, V. M. Danilova
Palladin Institute of Biochemistry, National Academy of Sciences of Ukraine, Kyiv;
e-mail: tto@biochem.kiev.ua
The paper presents the results of inventive activity of the Laboratory of Biologics Technology of the Palladin Institute of Biochemistry, NAS of Ukraine, under the leadership of Z.M.Datsenko, Cand.Sc. (Biol.), during 1991-2010. The laboratory researchers have developed new technologies for production of medicines of lipid-protein nature, which are based on endogenous complexes of biologically active substances included in the composition of biomembranes of different origin. The researchers have created new technologies for drug PANTOCRINE (for injections and oral administration) from antlers of deers and horns of farm animals that have significantly higher biological activity compared with the commercial drug. They have also created new biologically active drugs from antlers with a specific action: HIPPOCAMP, reducing blood pressure in various forms of hypertension, and PANTERON – biological regulator of synthesis of steroid hormones. Further the researchers have developed technologies for obtaining biologically active complexes of various specific action from marine organisms (calamari, clams mussels, shellfish): CALMOFIL and MOLUFIL, therapeutic agents for replacement therapy of surfactant system of the lungs; FILOMEK, the agent for prophylaxis and treatment of a human reproductive system disorders; MOLUSTERON, the glicolipopeptide complex, three individual physiologically active compositions being differentially obtained from the latter: lipopeptide composition – for treatment of hypertension, nucleopeptide one – for treatment of hormonal disorders, and phospholipid – for treatment of lung diseases under the surfactant shortage.